Market closed
Metagenomi/MGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Metagenomi
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).
Ticker
MGX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
228
Website
Metagenomi Metrics
BasicAdvanced
$72M
Market cap
-
P/E ratio
-$5.04
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$72M
52-week high
$12.74
52-week low
$1.87
Average daily volume
268K
Financial strength
Current ratio
5.824
Quick ratio
5.737
Long term debt to equity
15.791
Total debt to equity
17.794
Management effectiveness
Return on assets (TTM)
-13.92%
Return on equity (TTM)
-28.98%
Valuation
Price to revenue (TTM)
0.511
Price to book
0.27
Price to tangible book (TTM)
0.27
Price to free cash flow (TTM)
-0.269
Growth
Revenue change (TTM)
83.36%
Earnings per share change (TTM)
-68.27%
What the Analysts think about Metagenomi
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Metagenomi stock.
Metagenomi Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Metagenomi Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Metagenomi News
AllArticlesVideos
The Schall Law Firm Encourages Investors With Losses To Join A Case Against Metagenomi Inc For Securities Law Violations
Accesswire·13 hours ago
MGX LAWSUIT ALERT: Levi & Korsinsky Notifies Metagenomi, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Accesswire·17 hours ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 25, 2024 in Metagenomi Lawsuit - MGX
Accesswire·18 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Metagenomi stock?
Metagenomi (MGX) has a market cap of $72M as of October 12, 2024.
What is the P/E ratio for Metagenomi stock?
The price to earnings (P/E) ratio for Metagenomi (MGX) stock is 0 as of October 12, 2024.
Does Metagenomi stock pay dividends?
No, Metagenomi (MGX) stock does not pay dividends to its shareholders as of October 12, 2024.
When is the next Metagenomi dividend payment date?
Metagenomi (MGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Metagenomi?
Metagenomi (MGX) does not currently have a Beta indicator.